except for the active substance. (microcrystalline cellulose

DRUG2 trials

Sponsors

University Medical Center Utrecht, Universitair Medisch Centrum Utrecht

Conditions

MonkeypoxPASC: post-acute sequelae of SARS-CoV-2 infection

Phase 3

RECLAIM: an Adaptive Platform Trial for the Evaluation of Treatments for Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

RecruitingCTIS2024-511580-28-02

Universitair Medisch Centrum UtrechtPASC: post-acute sequelae of SARS-CoV-2 infection

Start: 2025-02-20Target: 2000Updated: 2025-09-04

Phase 4

European Randomised Clinical Trial on mPOX Infection (EPOXI)

CompletedCTIS2022-501979-10-00

University Medical Center UtrechtMonkeypox

Start: 2024-08-08End: 2025-07-14Target: 335Updated: 2025-06-26

Related Papers

The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol

Trials2026-02-19